Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

J. Small, Eric; F. Schellhammer, Paul; S. Higano, Celestia; H. Redfern, Charles; Nemunaitis, John; H. Valone, Frank; Verjee, Suleman; Jones, Lori; M. Hershberg, Robert

doi:10.1200/jco.2005.04.5252

Public

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

Published in Journal of Clinical Oncology • Jun 30, 2006

Authors:

Eric J. Small

Paul F. Schellhammer

Celestia S. Higano

Abstract

PURPOSE: Sipuleucel-T (APC8015) is an investigational immunotherapy product designed to stimulate T-cell immunity against prostatic acid phosphatase. A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study. PATIENTS AND METHODS: A total of 1...

Subject

Medicine

Internal medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!